Overview

Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in HIV-Infected Infants Receiving Combination Antiretroviral Therapy

Status:
Completed

Trial end date:
2021-02-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and antiviral activity of VRC01 in HIV-1-infected infants beginning combination antiretroviral therapy (cART).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Treatments:

Anti-Retroviral Agents
Antibodies
Antibodies, Monoclonal